期刊文献+

淋巴瘤患儿血清铁调素、IL-6的水平变化及意义 被引量:10

下载PDF
导出
摘要 目的观察淋巴瘤患儿血清中铁调素(Hepcidin)和白细胞介素6(IL-6)水平变化,并探讨其临床意义。方法选取初治并排除骨髓浸润的淋巴瘤患儿69例,分为贫血组15例、非贫血组54例,另选取健康体检儿童15例作为正常对照组。用ELISA法检测淋巴瘤患儿及正常对照组儿童血清Hepcidin和IL-6水平,分析血清Hepcidin和IL-6水平与贫血的关系。结果贫血组、非贫血组、正常对照组血清Hepcidin水平分别为(38.93±14.12)、(31.26±11.01)、(21.99±5.14)ng/m L,IL-6水平分别为(12.13±1.92)、(10.23±1.67)、(8.59±1.01)pg/m L,3组血清Hepcidin和IL-6水平比较差异有统计学意义(P均<0.05)。贫血组Hepcidin水平与血红蛋白水平呈负相关(r=-0.765,P=0.003),Hepcidin水平与IL-6呈正相关(r=0.657,P=0.014)。结论淋巴瘤贫血患儿血清Hepcidin、IL-6水平升高,二者在儿童淋巴瘤相关贫血中发挥重要作用。
出处 《山东医药》 CAS 北大核心 2016年第9期62-64,共3页 Shandong Medical Journal
  • 相关文献

参考文献2

二级参考文献25

  • 1[1]Birgegard G,Gascon P,Ludwig H.Evaluation of anaemia in patients with multiple myeloma and lymphoma:findings of the European CANCER ANAEMIA SURVEY[J].Eur J Haematol,2006,77(5):378-386.
  • 2[2]Curt G,Johnston PG.Cancer fatigue:the way forward[J].Oncologist,2003,8(1):27-30.
  • 3[3]Caro JJ,Salas M,Ward A,et al.Anemia as an independent prognostic factor for survival in patients with cancer:a systemic,quantitative review[J].Cancer,2001,91(12):2214-2221.
  • 4[4]Barrett-Lee PJ,Ludwig H,Birgegard G,et al.European Cancer Anaemia Survey Advisory Board and Participanting Centers.Independent risk factors for anemia in cancer patients receiving chemotherapy:results from the European Cancer Anaemia Survey[J].Oncology,2006,70(1):34-48.
  • 5[5]Sieniawski M,Franklin J,Nogova L,et al.Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favomble Hodgkin's lymphoma[J].J Clin Oncol,2007,25(15):2000-2005.
  • 6[6]Birgegard G,Aapro MS,Bokemeyer C,et al.Cancer-related anemia:pathogenesis,prevalence and treatment[J].Oncology,2005,68(1):3-11.
  • 7[7]Ludwig H,Van Belle S,Barrett-Lee P,et al.The European Cancer Anaemia Survey(ECAS):a large,multinational,prospective survey defining the prevalence,incidence,and treatment of anaemia in cancer patients[J].Eur J Cancer,2004,40(15):2293-2306.
  • 8[8]Henry DH,Dahl NV,Auerbach M,et al.Intravenous ferric gluconate significantly impmves respense to epoetin alfa versus oral iron or no iron in anemic patients with cancer receiving chemotherapy[J].Oncologist,2007,12(2):231-242.
  • 9[9]Osterborg A,Steegmann JL,Hellmann A,et al.Phase Ⅱ study of three dose levels of continuous erythropoietin receptor activator(C.E.R.A.)in anaemic patients with aggressive nonHodgkin's lymphoma receiving combination chemotherapy[J].Br J Haematol,2007,136(5):736-744.
  • 10[10]Rizzo JD,Lichtin AE,Woolf SH,et al.Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology[J].Blood,2002,100(7):2303-2320.

共引文献5

同被引文献87

引证文献10

二级引证文献44

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部